ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Clinical Trials
1.1k
Trial Phases
5 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (827 trials with phase data)• Click on a phase to view related trials
Expanded Access to Tavapadon
- Conditions
- Parkinson Disease
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- AbbVie
- Registration Number
- NCT07158827
- Locations
- 🇺🇸
Endeavor Health /ID# 277884, Northbrook, Illinois, United States
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Conditions
- Geographic AtrophyAge-Related Macular Degeneration
- Interventions
- Drug: ABBV-6628
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 66
- Registration Number
- NCT07160179
- Locations
- 🇺🇸
Retina Partners Midwest, P.C. /ID# 262172, Carmel, Indiana, United States
🇺🇸Retina Foundation of the Southwest /ID# 262479, Dallas, Texas, United States
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 730
- Registration Number
- NCT07155174
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2025-09-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 430
- Registration Number
- NCT07155187
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 258
- Registration Number
- NCT07145918
- Locations
- 🇺🇸
Woodland International Research Group /ID# 275747, Little Rock, Arkansas, United States
🇺🇸Collaborative Neuroscience Research - Garden Grove /ID# 273005, Garden Grove, California, United States
🇺🇸Community Clinical Research - Austin - Cross Park Drive /ID# 272977, Austin, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 222
- Next
News
Biohaven Prepares for Potential First-in-Class Spinocerebellar Ataxia Drug Launch as FDA Decision Looms
Biohaven's Vyglxia could become the first approved treatment for spinocerebellar ataxia, a rare genetic brain disorder affecting movement and coordination, with FDA decision expected between October and December.
Johnson & Johnson Discontinues Nipocalimab Combination Therapy for Rheumatoid Arthritis After Phase 2a Trial Fails to Show Added Benefit
Johnson & Johnson has terminated development of nipocalimab in combination with anti-TNF-alpha therapies for rheumatoid arthritis after the 12-week Phase 2a DAISY trial failed to demonstrate significant clinical benefits over anti-TNF-alpha therapy alone.
Controlled Release Drug Delivery Market Expands with Major Pharma Investment in Precision Medicine Technologies
Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.
Schrödinger Discontinues Blood Cancer Drug SGR-2921 After Two Patient Deaths in Phase I Trial
Schrödinger has terminated development of its CDC7 inhibitor SGR-2921 after two patient deaths in a Phase I trial for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
AbbVie Invests $195 Million to Expand U.S. API Manufacturing Capacity in North Chicago
AbbVie announced a $195 million investment to expand active pharmaceutical ingredient (API) production capacity at its North Chicago, Illinois manufacturing facility.
REGENXBIO Advances Gene Therapy to Pivotal Phase IIb/III Trial for Diabetic Retinopathy
REGENXBIO will initiate a pivotal Phase IIb/III clinical trial for surabgene lomparvovec in diabetic retinopathy using suprachoroidal delivery, following positive two-year safety and efficacy data from the Phase II ALTITUDE trial.
Vitiligo Treatment Pipeline Shows Promise with JAK Inhibitors and Novel Immunotherapies in Phase 3 Trials
Over 18 companies are actively developing 20+ pipeline therapies for vitiligo treatment, with JAK inhibitors leading the charge in late-stage clinical trials.
RIPK1 Inhibitor Pipeline Shows Promise Despite Sanofi Setback in Multiple Sclerosis
Over 10 companies are developing 12+ RIPK1 inhibitor therapies targeting inflammatory and neurodegenerative diseases, with key players including Sanofi, Rigel Pharmaceuticals, and GenFleet Therapeutics advancing promising candidates.
Syndax Reports Strong Q2 2025 Results with Revuforj Revenue Growth and Pending FDA Approval for NPM1 AML
Syndax Pharmaceuticals reported $28.6 million in Revuforj net revenue for Q2 2025, representing a 43% increase over the first quarter despite approximately one-third of patients pausing treatment for stem cell transplants.
AbbVie's Rinvoq Achieves Breakthrough Results in Alopecia Areata Phase III Trial
AbbVie's Rinvoq demonstrated significant efficacy in a Phase III trial for alopecia areata, with 47.1% of patients achieving 90% or more scalp hair coverage on the 30mg dose versus 1.4% on placebo.